Sepsis
Sepsis: a major global challenge
49 million cases and 11 million deaths in 2017
$5.1B spent on treatment and diagnosis in 2024
6–8% annual market growth expected through 2030
$52B annual cost to U.S. healthcare systems in 2021
A critical unmet need
Clinicians lack a reliable, early biomarker to quickly diagnose and assess sepsis severity.
Early detection is essential to improve survival and reduce healthcare costs.
There is a pressing need for an efficient point-of-care test to evaluate patient severity as soon as they arrive in intensive care or emergency units.
It is essential to develop an efficient point-of-care marker to rapidly assess the clinical severity of patients upon admission to intensive care or emergency departments.
Pr Sami Hraiech
Red blood cell deformability: an early prognostic and severity biomarker in sepsis
Our value proposition
With DYNARED technology, we empower clinicians with a rapid, high-performance decision-support tool to:
– Optimize public healthcare costs
– Improve early diagnosis and treatment outcomes
– Increase patient survival rates
- Katia Donadello et al. Reduced red blood cell deformability over time is associated with a poor outcome on septic patients, Microvascular Research 2015, DOI: 10.1016/j.mvr.2015.05.001
- A.G. Moutzouri et al. Red blood cell deformability in patients with sepsis: A marker for prognosis and monitoring of severity, Clin. Hemorheol. Microcirc. (2007), PMID: 17502699